Peritoneal Metastases Clinical Trials

11 recruiting

Peritoneal Metastases Trials at a Glance

17 actively recruiting trials for peritoneal metastases are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Shanghai, Ghent, and Gothenburg. Lead sponsors running peritoneal metastases studies include Ruijin Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, and Department of Surgery, University of Adelaide, TQEH.

Browse peritoneal metastases trials by phase

Treatments under study

About Peritoneal Metastases Clinical Trials

Looking for clinical trials for Peritoneal Metastases? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Peritoneal Metastases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Peritoneal Metastases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 2

The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies

Peritoneal Metastases
The University of Hong Kong60 enrolled1 locationNCT06367270
Recruiting
Phase 2

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Peritoneal Metastases From Gastric CancerGastric Cancer Stage IVGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital74 enrolled1 locationNCT07556640
Recruiting
Not Applicable

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

Colorectal AdenocarcinomaPeritoneal MetastasesAppendiceal Cancer
Yale University20 enrolled1 locationNCT07291180
Recruiting
Phase 2

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Peritoneal MetastasesGastric Cancer Stage IV
Ruijin Hospital40 enrolled1 locationNCT06519591
Recruiting
Not Applicable

Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.

Peritoneal CarcinomatosisPeritoneal Metastases From Colorectal Cancer
Hospices Civils de Lyon58 enrolled1 locationNCT06929013
Recruiting

Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer

Gastric Cancer (GC)HIPECPeritoneal Metastases From Gastric Cancer+1 more
Ukrainian Society of Clinical Oncology200 enrolled1 locationNCT07313579
Recruiting
Phase 3

Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis

Gastric Cancer Peritoneal Metastases
Magnus Nilsson262 enrolled5 locationsNCT07304271
Recruiting
Phase 1

CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases

Peritoneal Metastases From Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University12 enrolled1 locationNCT07247396
Recruiting

On-treatment Biomarkers in Metastatic Colorectal Cancer for Life

Metastatic Colorectal CancerChemotherapy EffectPeritoneal Metastases+2 more
Region Skane100 enrolled2 locationsNCT05755672
Recruiting
Phase 1

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Peritoneal CarcinomatosisPeritoneal Metastases
University Hospital, Ghent45 enrolled1 locationNCT05277766
Recruiting
Phase 1

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

Liver CancerEsophageal CancerGastric Cancer+9 more
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)18 enrolled1 locationNCT07001592
Recruiting
Phase 1

PIPAC for Peritoneal Metastases

Peritoneal Metastases
National Cancer Centre, Singapore25 enrolled1 locationNCT04956068
Recruiting

Effect of intraoperative warmed, humidified carbon dioxide insufflation in open laparotomy colorectal surgery patients undergoing Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS HIPEC): a randomized controlled trial (Second WHCO2 trial)

Peritoneal Metastases
Sydney Local Health District60 enrolled1 locationACTRN12623000950662
Recruiting
Phase 2

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Unresectable Colon Cancer Peritoneal MetastasesPMMR/Ras/BRAF Wild-type
Second Affiliated Hospital, School of Medicine, Zhejiang University30 enrolled1 locationNCT05742425
Recruiting

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Gastric CancerPeritoneal Metastases
Chinese Academy of Sciences400 enrolled13 locationsNCT05722275
Recruiting
Phase 2

Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients

Peritoneal CarcinomatosisColo-rectal CancerPeritoneal Metastases+1 more
Michael Bau Mortensen60 enrolled1 locationNCT03280511
Recruiting

The Safety And Feasibility of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) in the treatment of Unresectable Disseminated Peritoneal Malignancy

Peritoneal Metastases
Department of Surgery, University of Adelaide, TQEH112 enrolled1 locationACTRN12618001017213